•
Shanghai Fosun Pharmaceutical Group Co. (HKG: 2196, SHA: 600196) is reportedly considering the sale of its India-based majority-owned Gland Pharma Ltd (BOM: 543245), according to a Bloomberg report. This follows interest from potential buyers, as cited by insiders. Market Interest and Early StagesFosun is reportedly in the early stages of…
•
Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) announced that its India-based subsidiary, Gland Pharma Ltd (BOM: 543245), plans to acquire privately held French pharmaceutical firm Cenexi for EUR 120 million (USD 124 million). In addition to the purchase price, Fosun Pharma will provide shareholder loans to Cenexi, with the total…
•
China-based Luye Pharma Group (HKG: 2186) has announced the first patient dosing in a Phase II clinical study for its Category 1 drug candidate, LY 03014. The multi-center, randomized, double-blind, placebo-controlled, and positive drug parallel control study aims to assess the preliminary efficacy and safety of the drug in treating…
•
The national high-value medical consumables alliance procurement office has released the results of the successive procurement of coronary artery drug-eluting stent systems following the expiration of volume-based procurement (VBP) agreements. A total of 14 products from 10 manufacturers were awarded spots, according to the document, which is open for public…
•
China-based Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456) has received approval from the China Securities Regulatory Commission (CSRC) to conduct a private placement of 70 million shares. The company plans to raise RMB 2.5 billion (USD 350 million) through this transaction, with proceeds allocated towards the Phase 1 construction of…
•
China-based Frontier Biotechnologies Inc. (SHA: 688221) has announced a collaboration agreement with the Chinese Association of STD and AIDS Prevention and Control (CASAPC) to facilitate precision prevention and control of AIDS in China. The partnership aims to enhance the effectiveness of existing measures and better allocate resources for combating the…
•
Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in a head-to-head bridging study for its programmed death-1 (PD-1) inhibitor, HanSiZhuang (serplulimab). The study is evaluating serplulimab as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) against Roche’s PD-L1 inhibitor Tecentriq (atezolizumab), the…
•
JancsiTech, a precision nuclear medicine specialist based in Shenzhen, has reportedly raised “tens of millions” of renminbi in an angel financing round led by Yuanbio Venture Capital. Existing investor Sequoia Capital China also participated in the round. The proceeds will be directed towards research and development, innovation of intelligent medical…
•
US-based Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) announced last week that its New Drug Application (NDA) for poziotinib, a treatment for previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations, received a complete response letter (CRL) from the US FDA. The CRL cited…
•
Sino Biological, Inc. (SHE: 301047) has announced plans to invest RMB 1 billion (USD 140 million) to create a one-stop biological reagent and technology service platform. The initiative also includes the development of a comprehensive bio-pharmaceutical innovation service park in the Beijing Economic-Technological Development Area. As of the announcement date,…
•
China-based Luye Pharma Group (HKG: 2186) has officially launched its Category 1 chemical drug toludesvenlafaxine (LY03005) in China. The extended-release treatment for depression has received its first prescriptions and is being launched through a multi-channel strategy that includes hospitals, pharmacies, and online platforms. Drug Profile and MechanismToludesvenlafaxine is a new…
•
Researchers at the University of Hong Kong have published the results of a study that identifies a potential new therapeutic target for epilepsy treatment. The research builds on recent findings regarding the role of neuroinflammation caused by abnormal reactive glial cells, including astrocytes and microglia, in temporal lobe epilepsy (TLE).…
•
China-based Hope Medicine Inc. has announced receiving approval to conduct a global multi-center Phase II clinical study for its monoclonal antibody (mAb) HMI-115, targeting the prolactin receptor (PRL R). The drug is being evaluated as a treatment for endometriosis, a condition that affects many women worldwide. This potential first-in-class (FIC)…
•
Shanghai-headquartered Full-Life Technologies Ltd has announced the acquisition of New Jersey-based Focus-X Therapeutics. The move is expected to significantly expand Full-Life’s pipeline, including two compounds nearing clinical trials, provide a second innovative peptide-focused discovery platform, and leverage its Radio Technology manufacturing and logistics platforms to advance compounds into clinical development.…
•
The National Medical Products Administration (NMPA) has released a notification regarding the initiation of two electronic certificates: the “Certificate for Exporting APIs to the EU” and the “Exporting Certificate of a Pharmaceutical Product.” These certificates aim to streamline the export process and enhance regulatory compliance. Details of the Certificates
•
China-based I-Mab (NASDAQ: IMAB) has announced a strategic partnership with compatriot firm Wuxi Diagnostics to accelerate biomarker-driven clinical studies and explore the cutting edge of companion diagnostics (CDx) development. Financial details of the partnership were not disclosed. Clinical and Development ContextWith the deepening of research on tumor pathogenesis, immunotherapy, particularly…
•
China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a pre-IPO financing round. The funding was led by Gree Financial Investment and KingRay Capital, with additional participation from Efung Capital, China Medical System Holdings (CMS; HKG: 0867), Wuxi Guolian Development (Group), and other investors. Technology…
•
China-based Alibaba Health Information Technology Ltd (HKG: 0241) has released its financial report for the first half of 2022 (ended September 30, 2022), recording total revenues of RMB 11.5 billion (USD 1.6 billion), representing a 22.9% year-on-year (YOY) increase. Business PerformanceAliHealth’s self-operated pharmaceutical direct sales business generated RMB 10.01 billion…
•
China-based 3D Medicines Inc. (HKG: 1244) is set to make an initial public offering (IPO) of 16.35 million shares on the Hong Kong Stock Exchange. The share price is expected to range from HKD 22.96 to 26.24 (USD 2.94 to USD 3.36) per share, with a maximum gross take-home of…
•
The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE) has released its summary of China’s trading situation in the health sphere during the first three quarters of 2022. According to Chinese government customs statistics, China recorded a medical product trade surplus in the period,…